4Peter G J.Process for the mamlfacture of gefitinib[P]:WO 2005 023 783,2004.
5Kleth H G.Quinazoline derivatives[P]:US 5 770 599,1996.
6Alexander J1 Bridges,Hairong Zhou.Tyrosie kinase inhibitors.8.An unu-sually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline(PD153035),a potent inhibitor of the epidermal growth factor receptor[J].J Med Chem,1996,39(1):267-276.
7Giday.PCT Int Appl[P].WO 023783,2005.
8Chandregowda V,Venkateshwara Rao G,Chandrasek hara Reddy G.Convergent approach for commercial synthesis of Gefitinib and erlotinib[J].Organic Process Research & Development,2007,11:813-816.
9Chandregowda V,Venkateshwara Rao G,Chandrasek hara Reddy G.One-pot conversion of 2-nitrobenzonitriles to quinazolin-4(3H)-ones and synthesis of Gefitinib and erlotinib hydrochloride[J].Heterocycles,2007,71:39-48.
10Murty M S R,Jyothirmai B,Yadav J D.Zinc mediated alkylation of cyclic secondary amines[J].Synthetic Communications,2003,33(14):2483-2486.
